Quadrant Capital Group’s Arbutus Biopharma ABUS Stock Holding History

Quadrant Capital Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-277	Closed	-$1.25K	–	1251
2026 Q1	$1.25K	Hold	277	–	–	﹤0.01%	2560
2025 Q4	$1.33K	Hold	277	–	–	﹤0.01%	2569
2025 Q3	$1.26K	Buy	+277	New	+$1.02K	﹤0.01%	2538
2025 Q2	–	Sell	-878	Closed	-$3.06K	–	1343
2025 Q1	$3.06K	Hold	878	–	–	﹤0.01%	2447
2024 Q4	$2.87K	Hold	878	–	–	﹤0.01%	2445
2024 Q3	$3.38K	Hold	878	–	–	﹤0.01%	2398
2024 Q2	$2.71K	Hold	878	–	–	﹤0.01%	2426
2024 Q1	$2.27K	Buy	878 +601	+217%	+$1.56K	﹤0.01%	2483
2023 Q4	$693	Sell	277 -635	-70%	-$1.24K	﹤0.01%	2587
2023 Q3	$1.85K	Buy	+912	New	+$1.91K	﹤0.01%	2411
2023 Q2	–	Sell	-205	Closed	-$622	–	2683
2023 Q1	$622	Hold	205	–	–	﹤0.01%	2579
2022 Q4	$478	Sell	205 -5,196	-96%	-$12.4K	﹤0.01%	2626
2022 Q3	$10K	Buy	+5,401	New	+$12.7K	﹤0.01%	1875

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quadrant Capital Group's ABUS Position: Q2 2026 in Review

Quadrant Capital Group sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 277 shares — an estimated $1.25K sold.

Quadrant Capital Group first reported a position in ABUS in Q3 2022 and held it in 13 quarters. The position peaked at $10K in Q3 2022. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Quadrant Capital Group reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 277 Arbutus Biopharma shares in Q2 2026, an estimated $1.25K.
Quadrant Capital Group first reported a position in Arbutus Biopharma in Q3 2022 and held it in 13 quarters.
Quadrant Capital Group's Arbutus Biopharma position peaked at $10K in Q3 2022.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.